Curevo gets $110M for a shot against Shingrix, gets Moncef Slaoui and Tal Zaks on board

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

TG Therapeutics to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy program, for the treatment of AD

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced they are

February 13, 2025

Hypothalamic Obesity Tx; Weekly Insulin Under Review; Ozempic Price Investigation

Setmelanotide, an investigational melanocortin-4 receptor agonist, reduced body mass index (BMI) by a mean 15% at 16 weeks and 26% at 12 months in people

May 1, 2024

FDA Calls for New Boxed Warning on All CAR-T Products

The FDA has called for new boxed warnings on the labeling of all approved chimeric antigen receptor (CAR) T-cell therapies over a potential risk for

January 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.